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Abstract: Endocrine Disrupting Compounds (EDCs) are chemical substances shown to interfere with
endogenous hormones affecting the endocrine, immune and nervous systems of mammals. EDCs are
the causative agents of diseases including reproductive disorders and cancers. This highlights
the urgency to develop fast and sensitive methods to detect EDCs, which are detrimental even at
very low concentrations. In this work, we propose a label-free surface plasmon resonance (SPR)
biosensor method to detect specific EDCs (17 β-estradiol (E2), ethinyl-estradiol, 4-nonylphenol,
tamoxifen) through their binding to estrogen receptor alpha (ERα). We show that the use of rationally
designed ERα (as bio-recognition element) in combination with conformation-sensitive peptides
(as amplification agent, resulting in increased responses) enables the detection of low parts per billion
(ppb) levels of E2. As a proof of concept, this bioassay was used to detect E2 in (spiked) real water
samples from fish farms, rivers and the sea at low ppb levels after concentration by solid phase
extraction. In addition, the present SPR assay that combines a conformation-sensitive peptide with an
array of ERα mutants is very promising for the assessment of the risk of potential estrogenic activity
for chemical substances.
Keywords: estrogen receptor; 17β-estradiol; label-free assay; surface plasmon resonance;
amplification; water
1. Introduction
Growing evidence in the last decades suggested that numerous chemicals, both natural and
man-made, may interfere with the endocrine system and produce adverse effects in animals and
humans. Scientists often refer to these chemicals as Endocrine Disrupting Compounds (EDCs).
These chemicals are found in many commercial products, such as plastic bottles, containers,
metal food cans, detergents, flame-retardants, food, toys, cosmetics, drugs and pesticides.
17β-Estradiol (E2) and other natural hormones, natural chemicals, man-made chemicals and
pharmaceutical products [1], are considered as EDCs because of their ability to mimic the effect of
endogenous hormones [2]. They can interfere with the endocrine, immune and nervous systems of
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mammals [3]. Many of these EDCs have been found in the environments at very low concentration [4],
but chronic low-level exposure might cause adverse biological effects in animals and humans [5].
For this reason, the REACH regulation (Registration, Evaluation, Authorisation and Restriction
of Chemicals) imposes high level of protection for human health and the environment to the
manufacturers of chemicals in the EU. To address these issues, simple, fast, accurate and sensitive
methods for screening these compounds are required [6]. The most sensitive methods currently
available for the detection of (anti)estrogenic activity are cell-based assays such as ER-CALUX,
MELN, T47D-KBLuc and the Yeast Estrogen Screen (YES) assays [7]. Although these methods have
been successfully developed to overcome animal testing and reach limit of detection of pg-ng/L,
they have the disadvantages to require 24 h for test completion and specific laboratories equipment
and personnel. In contrast, several bioanalytical techniques have been developed based on optical
and electrochemical detection, in which the bio-recognition elements are usually antibodies, enzymes,
receptors, nucleic acid, or whole cells [8]. Label free, antibody-based immuno-sensors have been used
for environmental detection of EDCs [9–13], but the cost and difficulties to produce specific antibodies
to different EDCs remains a limitation.
Interesting approaches using estrogen receptor proteins (ER) as a biorecognition element have
been proposed as alternative methods to the use of antibodies [10]. ERα is a member of the superfamily
of nuclear receptors [14–16] activating signaling pathways that regulate biological processes such as
reproduction, embryonic development and homeostasis [17–20]. ERα is composed by five domains,
three of which are well-structured functional domains: a modulating domain, a DNA-binding
domain (DBD) and a ligand binding domain (LBD) [21–23]. Binding of ligands to the LBD of
the wild type estrogen receptor (wt-ERαLBD) induces conformational changes, which in turn affect
and regulate the hormonal pathways. In the presence of agonist ligands the so-called helix 12,
which lies over the ligand-binding cavity, changes position in the presence of agonist or antagonist
ligands. Different positioning of helix 12 and associated changes in other helices of wt-ERα result
in different co-regulator binding surfaces and hence underlie the different physiological effects of
agonists and antagonists compounds [24–27]. Rationally designed mutants in the ERαLBD were
produced to increase the affinity towards specific agonist/antagonist compounds [28] by replacing
residue methionine (M) 421 with isoleucine (I) or phenylalanine (F). In comparison to wt-ERαLBD,
M421F-ERαLBD exhibits stronger binding affinity for E2, ethinyl-estradiol (EE2), and 4-nonylphenol
(4-NP) whereas M421I-ERαLBD has lower binding affinity for all investigated compounds compared to
wt-ERαLBD [28].
wt-ERα has been used to detect agonist/antagonist compounds in in vitro tests based on
bioaffinity mass spectroscopy [29] and surface plasmon resonance (SPR) approaches [30,31]. However,
the limits of detection are still orders of magnitude higher than those of cell culture bioassays.
The advantage of using bioanalytical tools is their direct applicability for continuous assessment
of EDCs [32]. SPR has been shown to be a versatile technique for biosensor applications [33]
and novel and portable SPR devices are under development [34]. In addition, direct detection of
agonist/antagonist compounds using label-free biosensors is challenging because their low molecular
weights (typically <500 Da) are close to the inherent limit of detection of most label-free techniques [31].
An interesting method to bypass this problem is to exploit the ability of ER to change conformation
upon ligand binding. Indeed, αβ/I peptide, a specific peptide motif belonging to ER interacting
proteins, was demonstrated to recognize the active conformation of wt-ERαLBD [35–37].
Here we propose an SPR based label free method that exploits both the ERαLBD and
a peptide (αβ/I) able to recognize the active conformation of agonist ligand bound ERαLBD.
Different compounds, such as E2, can act as ER agonist molecules, promoting an ER active conformation
that is specifically recognized by the αβ/I peptide. By contrast, binding of antagonist compounds such
as tamoxifen causes conformational changes that prevent ER from binding the αβ/I peptide. In our
proposed method, the specific binding of ligands is monitored through the ER interaction with the
αβ/I peptide immobilized on an SPR sensor surface and used as recognition and amplification element.
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The assay is performed by incubating ERαLBD with E2 and we show that the SPR binding response
is directly related to the concentration of ligand bound to ERαLBD. Moreover, screening of an array
of engineered estrogen receptors (wt-ERαLBD, M421F-ERαLBD, M421I-ERαLBD and Y537S-ERαLBD)
with a set of agonist and antagonist ligands shows that the assay is a fast method to detect the
estrogenic activities of E2, EE2, 4-NP and tamoxifen. As a proof of concept, the wt-ERαLBD-based
assay was applied to the detection of estrogen activity in water samples; the procedure and
experimental conditions were adapted to create a robust and reproducible assay with great promise
for future applications.
2. Materials and Methods
2.1. Materials and Reagents
Endocrine disrupting compounds (EDCs) such as 17β-estradiol (E2), ethinyl-estradiol(EE2),
4-nonylphenol (4-NP) and 4-OH tamoxifen (TAM) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Stock solutions of all ligands were prepared in methanol; for SPR measurements, the stock
solutions were further diluted with methanol into a series of concentrations, and then added to the
final working samples in order to obtain the right ligand concentration and a final methanol percentage
of 2%. Biotinylated-Dioxa (AEEA) and amine terminated peptides αβ/I (SSNHQSSRLIELLSR) are
synthesized by Primm Srl (Milan, Italy). All the other reagents were acquired from general laboratory
suppliers with analytical purity. Solutions were prepared in deionized water from water purification
system MMilli-Q® Integral (Millipore-Merck, Burlington, MA, USA).
2.2. ERαLBD Production and Purification
Wild-type ERαLBD and its mutants were expressed in high yield in E. coli Rosetta 2(DE3)pLysS
cells with a pET21 vector (Novagen) and then purified as previously described [28].
Single point mutants were generated by site-directed mutagenesis of the vector encoding the
wild-type sequence using the QuickChange site-directed mutagenesis kit (Stratagene). The introduction
of the desired mutations was confirmed by DNA sequencing. The PCR products are transformed into
XL10-Blue supercompetent E. coli cells (Stratagene) and the plasmids purified according to standard
techniques and transferred in E. coli Rosetta 2(DE3)pLysS cells for protein production.
2.3. Design of the Binding Assay
The SPR label-free binding assay is based on the ability of αβ/I peptide to recognize a ligand
bound conformation of ER (also called active conformation upon agonist binding). Figure 1 is a
schematic representation of the assay: αβ/I biotinylated peptide (peptide in yellow) able to recognize
the active conformation of the ERαLBD (violet) was directly immobilized on a neutravidin coated
surface. After immobilization of the αβ/I, pre-incubated ERαLBD-ligand complex solutions were
flowed over the peptide functionalized surface and the binding event of ERαLBD-ligand onto αβ/I
peptide was monitored. In case an agonist molecule (magenta) is bound to ERαLBD, helix 12 (green)
moves creating a conformation that is recognized by the αβ/I peptide. When ERαLBD is free
(un-liganded) or antagonist bound (orange), helix 12 might create a conformation that is not recognized
by the αβ/I peptide.
Monitoring the amount of ERαLBD-E2 complex bound onto αβ/I peptide is a direct detection of
E2, because the amount of detected ERαLBD-E2 is proportional to the E2 concentration. The advantage
of this assay format is that it is based on the recognition of a large molecule (the ERαLBD-E2 complex is
around 29 kDa), which circumvents the issue related to the detection of small molecules (for instance
E2 is 273.82 Da) with low responses in SPR-based detection methods.
Biosensors 2018, 8, 1 4 of 15
Biosensors 2017, 8, 1  4 of 14 
 
Figure 1. Schematic representation of the approach used for the detection of ERαLBD agonist and 
antagonist compounds. 
2.4. SPR Measurements 
2.4.1. ProteOn XPR36™ 
All the binding experiments were performed with a ProteOn XPR36™ SPR instrument (BioRad), 
at 25 °C using a neutravidin modified chip (NLC sensor chip, BioRad, Hercules, CA, USA). With this 
instrument a 6 × 6 interaction array for the simultaneous analysis of thirty-six different experimental 
conditions was generated. NLC is a sensor chip with a neutravidin protein immobilized into a matrix 
of alginate polymer. The further coupling on the chip exploits the specific binding between 
neutravidin and biotinylated molecules. The chip was activated according to the manufacturer’s 
instructions by sequentially injecting 1 M NaCl and 50 mM NaOH for 60 s at 30 µL/min. The 
immobilization of biotinylated peptide (αβ/I) on the NLC chip surface was done in 20 mM Tris-HCl, 
pH 8, 20 mM NaCl (buffer A) for 300 s at 30 µL/min. The subsequent injection of ERαLBD-ligand 
complex was done in 100 mM potassium phosphate buffer, pH 7.2, 20 mM NaCl, 2% methanol (buffer 
B) for 240 s at 100 µL/min. The biotinylated αβ/I peptide was immobilized in vertical way (left panel, 
Figure S1) and the peptide surface was, then, washed with buffer B for one hour. ERαLBD-ligand 
complexes were then flowed over the αβ/I peptide in horizontal way (right panel, Figure S1), and its 
binding was monitored.  
For each binding measurement, triplicate independent solutions were prepared for receptor-
ligand mixture under investigation. Error was calculated using triplicates. 
To assess the amount of immobilized peptide leading to an optimal SPR response, five different 
concentrations of peptides (0.1, 0.6, 1.4, 2.2 and 17 µg/mL) were injected in 5 channels (Figure S1, 
vertical way), and one channel was used as reference with buffer A. 
To determine the best peptide concentration for ERαLBD-ligand binding, a mixture of ERαLBD  
(4 µg/mL, 134 nM) and E2 (405 ng/mL, 1.5 µM) was prepared and flowed over the different peptide 
concentrations. Buffer B and free ERαLBD were injected at the same time as controls.  
To determine the limit of quantification of our assay, mixtures of wt-ERαLBD (134 nM) were 
prepared and incubated with different E2 concentrations (0.03, 0.3, 0.8, 2.7, 4, 8, 12, 27 ng/mL and  
405 ng/mL). Buffer solution and wt-ERαLBD without ligand were prepared and injected at the same 
time as controls. After each measurement, the peptide functionalized surface was regenerated by 
injecting 10 mM H3PO4 for 20 s at 100 µL/min in both flow directions to remove the ERαLBD-ligand 
complex from the modified functionalized peptide surface. Triplicate measurements were performed 
for each receptor-ligand concentration under investigation.  
To test the specific interaction of the estrogen receptors towards the αβ/I peptide, the same 
experiments of binding were performed with transthyretin protein (TTR), which is not supposed to 
Figure 1. Schematic representation of the approach used for the detection of ERαLBD agonist and
antagonist compounds.
2.4. SPR Measurements
2.4.1. ProteOn XPR36™
All the binding experiments were performed with a ProteOn XPR36™ SPR instrument (BioRad),
at 25 ◦C using a neutravidin modified chip (NLC sensor chip, BioRad, Hercules, CA, USA). With this
instrument a 6 × 6 interaction array for the simultaneous analysis of thirty-six different experimental
conditions was generated. NLC is a sensor chip with a neutravi in protein immobilized into a matrix
of alginate polymer. Th further coupl on the chip exploits the specific binding betwee neutravidin
and biotinylated molecules. The chip was activated according to the manufacturer’s instructions by
sequentially injecting 1 M NaCl and 50 mM NaOH for 60 s at 30 µL/min. The immobilization of
biotinylated peptide (αβ/I) on the NLC chip surface was done in 20 mM Tris-HCl, pH 8, 20 mM
NaCl (buffer A) for 300 s at 30 µL/min. The subsequent injection of ERαLBD-ligand complex was done
in 100 mM potassium phosphate buff r, pH 7.2, 20 mM NaCl, 2% meth nol (b ffer B) for 240 s at
100 µL/min. The bioti ylated αβ/I peptide was immobilized in vertical way (left panel, Figure S1) and
the peptide surface was, then, washed with buffer B for one hour. ERαLBD-ligand complexes were then
flowed over the αβ/I peptide in horizontal way (right panel, Figure S1), and its binding was monitored.
For each binding measurement, triplicate independent solutions were prepared for receptor-ligand
mixture under investigation. Error was calculated using triplicates.
To assess the a ount of immobilized peptide leading to an optimal SPR response, five different
concentrations of peptides (0.1, 0.6, 1.4, 2.2 and 17 µg/mL) were injected in 5 channels (Figure S1,
vertical way), and one channel was used as reference with buffer A.
To determine the best peptide concentration for ERαLBD-ligand binding, a mixture of ERαLBD
(4 µg/mL, 134 nM) and E2 (405 ng/mL, 1.5 µM) was prepared and flowed over the different peptide
concentrations. Buffer B and free ERαLBD were inj cted at the s m time s controls.
To d termine the limit f quantification of our assay, mixtures of wt-ERαLBD (134 M) were
prepared and incubated with different E2 concentrations (0.03, 0.3, 0.8, 2.7, 4, 8, 12, 27 ng/mL and
405 ng/mL). Buffer solution and wt-ERαLBD without ligand were prepared and injected at the same
time as controls. After each measurement, the peptide functionalized surface was regenerated by
injecting 10 mM H3PO4 for 20 s at 100 µL/min in both flow directions to remove the ERαLBD-ligand
complex from the modified functionalized peptide surface. Triplicate measurements were performed
for each receptor-ligand concentration under investigation.
To test the specific interaction of the estrogen receptors towards the αβ/I peptide, the same
experiments of binding were performed with transthyretin protein (TTR), which is not supposed to
bind the peptide. TTR at 134 nM, without and with E2 at 1.5 µM was injected onto the peptide coated
surface and the SPR signal monitored.
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Furthermore, experiments were performed to determine the affinity of the αβ/I peptide to the
wt-ERαLBD-E2 complex. Serial dilutions of wt-ERαLBD-E2 were prepared starting from wt-ERαLBD
134 nM and E2 200 nM, then diluting 1:2 for five times. The wt-ERαLBD-E2 complex solutions were
then flushed over the peptide coated surface and each binding curve is fitted to Langmuir isotherm.
To screen the binding abilities of ERαLBD mutants bound to selected ligands, receptors were
pre-incubated and then flowed over the peptide surface. Respectively 134 nM wt-ERαLBD,
M421F-ERαLBD, M421I-ERαLBD and Y537S-ERαLBD were injected as free receptor, or incubated with
1.5 µM E2, EE2, 4-NP and TAM. The reference solutions were prepared by adding 2% methanol to
buffer B alone and to ERαLBD solutions without ligand. ERαLBD-ligand, ERαLBD-methanol and the
buffer-methanol mixtures were incubated for 1 h at 4 ◦C. Triplicate solutions were prepared for each
receptor-ligand mixture under investigation.
2.4.2. Biacore 3000
The binding experiments and water sample analyses were performed with a Biacore 3000 and
carried out by immobilization of the amine-peptide directly to a CM5 chip. The amine terminated
αβ/I peptide was dissolved in acetate-buffer (pH 4.5) in a concentration of 100 µg/mL and injected
over an EDC/NHS activated CM5 chip surface and a response of 800 RU was recorded.
The final optimized assay conditions were as follows: 100 µL of the wt-ERαLBD (60 nM) in HBS-EP
(10 mM Hepes, 150 mM NaCl, 3 mM EDTA, 0.005% Tween-20) buffer was mixed in the Biacore with
100 µL of E2 standard/sample in 20% methanol and of this mixture 90 µL was injected at 30 µL/min
with HBS-EP as running buffer which was followed by the injection of 10 mM NaOH for 0.5 min for
the regeneration. For calibration, E2 concentrations of 0.63, 1.25, 2.5, 5, 10 and 20 ng/mL were used.
This bioassay was then used to test (spiked) Milli Q (MQ) water, tap drinking water, tap process water,
real field water samples from fish tanks coming from the UK and river and sea water samples coming
from Slovenia. The water samples were spiked with different concentrations of E2 (10, 20 or 50 ng/L
(ppt)) and concentrated with by Solid Phase Extraction (SPE) for 200 times prior to SPR assay. The final
sample extract contained 20% of methanol.
Furthermore, the real field water samples were analysed with the bioassay and the results
compared with GC-MS (Gas chromatography-mass spectrometry) data.
2.5. Water Sample Preparation by SPE
Field water samples were kept frozen until the day before being analysed. The thawed water
sample was filtered through a folder paper filter (S&S 595 1/2) with a pore size of 4–7 µm) followed by
an Acrodisc syringe filter of 0.45 µm (Pall) to avoid clogging of the SPE column (as was experienced
before). Sample volumes of 200 or 500 mL of the filtered water were brought to pH 5.2 by the addition
of 5 mL of acetate buffer (pH 5.2). Hereafter, 50 µL of Helix Pomatia was added and the whole
left overnight at 37 ◦C (mild shaking in a water bath). The column (Bond Elut C18 3 cc/500 mg of
Varian (1210–2028) was activated by passing through 2.5 mL of methanol followed by 2.5 mL sodium
acetate buffer (pH 4.8). The water sample was passed through the column, and thereafter the column
was washed with 1.5 mL of sodium acetate buffer, 3 mL of water, 1.5 mL sodium carbonate buffer,
3 mL water and 2 mL methanol/water (50/50; v/v). The column was dried and eluted with 4 mL of
acetonitrile. After overnight storage, the eluates contained solids and they were removed by filtration
(Whatman no. 1), the filter was washed with acetonitrile and it was evaporated and dissolved in
200 µL of methanol. This was divided in 4 portions of 50 µL, representing 50 mL of water sample each,
and stored in closed vials at 4–6 ◦C until analysed by the Biacore 3000.
2.6. GC-MS Analysis
The multi residue method (RIKILT SOP 1160) was developed for the detection of 27 anabolic
compounds (including E2 and EE2) from 0–1 µg/L. Of the methanol extracts of the water samples,
25 µL portions (equivalent to 25 mL of water) were evaporated and 25 µL of the derivatization reagent
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N-methyl-N-trimethyl silyltrifluoroacetamide (MSTFA) was added. The vials were vortexed and
the reaction mixture was incubated during 1 h at 60 ◦C. After incubation, the reaction mixture was
evaporated to dryness under a stream of nitrogen at 55 ◦C. The residue was dissolved in 50 µL of
isooctane and transferred into a glass injection insert and transferred into the automatic injector (Varian,
type CP-8400, Varian, Inc, Walnut Creek, CA, USA) of the GC-MS-MS (Varian type CP-3800 and type
1200 L, (Varian, Inc, Walnut Creek, CA, USA) and 2 µL were injected into the GC-column (VF-17MS,
30 m × 0.25 mm ID, film thickness 0.15 µm (Varian CP8981, Varian, Inc, Walnut Creek, CA, USA).
3. Results and Discussion
3.1. Optimisation of the Assay Parameters
Optimization of the procedure for peptide coating of the SPR surface and ERαLBD concentration
was performed on the ProteOn XPR36™ (BioRad, Hercules, CA, USA). Biotinylatedαβ/I peptides were
immobilized on a neutravidin modified sensor chip to form a monolayer through the biotin-neutravidin
specific interaction. To determine the amount of immobilized peptide leading to an optimal SPR
response, five different αβ/I peptide concentrations (0.06, 0.25, 0.6, 1.0 and 7.5 µM) were flowed
over the sensor surface (Figure S2. SI, Panel A). Buffer A without peptide was used in the reference
channel (Figure S2. SI, Panel A, black continuous line). The amount of αβ/I peptide bound to
neutravidin on the surface was determined and the corresponding SPR response plotted versus the
peptide concentration in Figure S2. (SI, Panel B). A maximum of 650 SPR response units (RU) was
determined for the peptide immobilization, with a signal variation of 8%. In addition, the binding
response reached a plateau for peptide concentrations higher than 1 µm.
For the optimization of the assay, E2 was chosen as model-ligand due to its high affinity towards
the ERαLBD binding pocket. Indeed, E2 generates the active conformation of ERαLBD (agonist bound)
specifically recognized by the αβ/I peptide. Preliminary tests with a range of ERαLBD concentrations
from 10 to 200 nM were performed to determine the optimal amount of receptor to be used for the
following experiments (data not shown).
wt-ERαLBD concentration of 134 nM was found to provide a high response signal and used for the
subsequent experiments. ERαLBD and E2 at the saturating concentration of 1.5 µM were pre-incubated
for 45 min at 4 ◦C and then injected on SPR channels functionalized with different amounts of αβ/I
peptide (Figure S3. SI).
The signal resulting from the binding of the wt-ERαLBD-E2 complex on the peptide-coated chip
increases with the amount of immobilized peptide (Figure S3. SI, Panel A). A signal plateau around
1100 RU, corresponding to the saturation of wt-ERαLBD-E2 complex on the surface, was found at
peptide concentration above 0.6 µM (Figure S3. SI, Panel B), which was selected for subsequent
experiments since it provides satisfactory signal to noise ratio and a good coverage of the surface.
Furthermore, the affinity of the αβ/I peptide to the wt-ERαLBD-E2 complex was measured as
described in materials and methods. An apparent average KD value of 2.5 × 10−9 ± 0.7 × 10−9 M
was determined.
The specificity of the interaction of the estrogen receptors with the αβ/I peptide in our assay was
verified by replacing ER with an unrelated protein with similar surface charge, TTR.
No SPR response was detected when 134 nM TTR, without and with E2 at 1.5 µM, was injected
over the αβ/I peptide coated surface (Figure S4. SI).
Reproducibility of the SPR measurements and regeneration of the chip surface were also tested.
After binding of wt-ERαLBD-E2 complex to the immobilized αβ/I peptide (Figure S5. SI, Step 1),
the ER was removed by washing the SPR chip with 10 mM H3PO4 at 30 µL/min for 18 s (contact time
with the chip) [38], regenerating the peptide surface for further testing (Figure S5. SI, Regeneration 1).
After regeneration, the wt-ERαLBD-E2 complex was flowed over the peptide surface as before.
The procedure was repeated twice (Figure S5. SI, Step 2, Regeneration 2, Step 3). Repeated injections
of the same wt-ERαLBD-E2 complex solution before and after regeneration gave similar SPR responses
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(Figure S5. SI) with reproducibility within 6% of variation. These experiments demonstrate that the
peptide coated surface can be successfully regenerated. The ease and effectiveness of the regeneration
steps and the reproducibility of the SPR response are a key asset for the assay. Furthermore, the
test can be completed in significantly shorter time than that required by cell-based assays. Surface
activation and peptide immobilization are performed in 20 min; injection of the wt-ERαLBD-E2 and
determination of its binding response are achieved in only 4 min. After that, the SPR chip can be
regenerated, washed and be ready for further ER injections and testing.
3.2. Limit of Detection, Sensitivity and Specificity of the Assay for wtERαLBD and E2
After optimization of the assay, the limit of detection (LoD) for the wtERαLBD-E2 system was
determined by preparing mixtures of 134 nM wt-ERαLBD with increasing amounts of E2, ranging from
0.1 to 1.5 µM. The wt-ERαLBD-E2 mixtures and the wt-ERαLBD ligand free solutions were prepared in
triplicate, incubated at 4 ◦C for one hour and injected over the sensor surface. E2 binding to wt-ERαLBD
generates an ER active conformation (agonist bound) specifically recognized by the αβ/I peptide.
Binding of ERαLBD to the immobilized peptide is expected to produce an SPR signal proportional to
the amount of E2, since the ER concentration is kept constant in our assay. The SPR responses for
different E2 concentrations are shown in Figure 2, Panel A. The SPR response recorded 60 s after the
end of injection was used for quantification purposes. Increasing concentrations of E2 generate a
proportional increase of signal response. Injection of ligand free wt-ERαLBD results in a SPR response
of 300 RU within 10% error, whereas wt-ERαLBD-E2 complex at 1.5 µM E2 shows a SPR response of
1200 RU within an error of 6%. The signal response can be fitted with a linear regression up to 30 nM
with R2 of 0.9. A plot of the SPR response of wt-ERαLBD-E2 binding to the αβ/I peptide versus the E2
concentration is shown in Figure 2, Panel B.
Biosensors 2017, 8, 1  7 of 14 
peptide coated surface can be successfully regenerated. The ease a d effective ess of the regeneration 
steps a d the reproducibility of the SPR response are a key asset for the assay. Furthermore, the test 
can be completed in significantly shorter time than that required by cell-based assays. Surface 
activation and peptide immobilization are performed in 20 min; injection of the wt-ERαLBD-E2 and 
determination of its binding response are achieved in only 4 min. After that, the SPR chip can be 
regenerated, washed and be ready for further ER injections and testing.  
3.2. Limit of Detection, Sensitivity and Specificity of the Assay for wtERαLBD and E2 
After optimization of the assay, the limit of de ection (LoD) for the wtERαLBD-E2 system was 
determined by preparing mixtures of 134 nM wt-ERαLBD with increasing amounts of E2, ranging from 
0.1 to 1.5 µM. The wt-ERαLBD-E2 mixtures and the wt-ERαLBD ligand free solutions were prepared in 
triplicate, incubated at 4 °C for one hour and injected over the sensor surface. E2 binding to wt-ERαLBD 
generates an ER active conformation (agonist bound) specifically recognized by the αβ/I peptide. 
Binding of ERαLBD to the immobilized peptide is expected to produce an SPR signal proportional to 
the amount of E2, since the ER concentration is kept constant in our assay. The SPR responses for 
different E2 concentrations are shown in Figure 2, Panel A. Th  SPR respons  recorded 60 s after the 
end of injection was used for quantification purposes. Increasing concentrations of E2 generate a 
proportional increase of signal response. Injection of ligand free wt-ERαLBD results in a SPR response 
of 300 RU within 10% error, whereas wt-ERαLBD-E2 complex at 1.5 µM E2 shows a SPR response of 
1200 RU within an error of 6%. The signal response can be fitted with a linear regression up to 30 nM 
with R2 of 0.9. A plot of the SPR response of wt-ERαLBD-E2 binding to the αβ/I peptide versus the E2 
concentration is shown in Figure 2, Panel B. 
 
Figure 2. (A) Surface plasmon resonance (SPR) sensorgrams of the interaction between 134 nM wt-
ERαLBD with different E2 concentrations (0.1, 1, 3, 10, 15, 30, 45, 100, 1500 nM); (B) The SPR signal 
recorded 60 s after the injection and is plotted as a function of E2 concentration. 
The limit of detection (LoD) was defined as the E2 concentration producing an SPR response 
above the response of the ligand free wt-ERαLBD (300 RU) plus 3 times the standard deviation  
(3 × 30 RU),corresponding to 1 nM or 0.20 ng/mL of E2. This LoD, although higher than that of  
LC-MS or radioimmunoassay based methods [39,40], this is equal or higher to the typical 
concentration of E2 found in contaminated real water samples. For instance, the concentration of E2 
in the river Ahr at Blankenheim is in the order of 4–12 ng/L [41] and 122–631 ng/L in Rio de la Plata, 
Argentina [42]. However, the LoD could be further improved by pre-concentrating the sample 
through, for instance, the use of SPE columns or miniaturized pre-concentration column tools as the 
one developed by Heub S. et al. [43].  
Figure 2. (A) Surface plasmon resonance (SPR) sensorgrams of the interaction between 134 nM
wt-ERαLBD with different E2 concentrations (0.1, 1, 3, 10, 15, 30, 45, 100, 1500 nM); (B) The SPR signal
recorded 60 s after the injection and is plotted as a function of E2 concentration.
The limit of detection (LoD) was defined as the E2 concentration producing an SPR response
above the response of the ligand free wt-ERαLBD (300 RU) plus 3 times the standard deviation
(3 × 30 RU),corresponding to 1 nM or 0.20 ng/mL of E2. This LoD, although higher than that of
LC-MS or radioimmunoassay based methods [39,40], this is equal or higher to the typical concentration
of E2 found in contaminat d eal water samples. For instance, the concentration of E2 in the river Ahr
at Blankenheim is in the order of 4–12 ng/L [41] and 122–631 ng/L in Rio de la Plata, Argentina [42].
However, the LoD could be further improved by pre-concentrating the sample through, for instance,
the use of SPE columns or miniaturized pre-concentration column tools as the one developed by
Heub S. et al. [43].
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3.3. Testing Water Samples
For testing water samples, the bioassay was optimized with just one wt-ERαLBD concentration
(1 µg/mL) and one αβ/I peptide amount (800 RU) coated on the chip surface, to create the fastest,
most robust and easiest to apply assay format suitable for routine testing. In this case, the amine
terminated αβ/I peptide was immobilized over an EDC/NHS activated CM5 chip. For calibration,
several solutions of wt-ERαLBD-E2 complex with different concentrations of E2 were prepared and
injected over the αβ/I peptide. This coated biosensor chip could be used for more than 150 injections
of samples/standards, and for weeks. The mixing (1:1; v/v) of the wt-ERαLBD solution (60 nM
(1 µg/mL in HBS-EP buffer)) with the standards and samples (in 20% methanol) was performed
automatically in the Biacore 3000 and at room temperature creating similar incubation times between
injections. No pre-incubation of the complex between wt-ERαLBD-E2 was applied because of the
limited effect on the SPR responses. Therefore, the assay was carried out faster. In addition, the amount
of methanol in the sample was varied between 0 and 20% and only a little signal reduction was
observed with methanol >2% but a clear difference between the blank and positive samples was
recorded. This result is very convenient because it allowed testing of the SPE eluate in methanol after
less dilution (5 times only). Moreover, the use of HBS-EP buffer, as ERα dilution and running buffer
showed larger differences between the blank and positive samples/standards in comparison to the
phosphate buffer. Regarding the stability of ERα, it was found that diluted ERα could be stored during
1 week at 4–6 ◦C which is convenient for routine testing, whereas better regeneration was recorded
by the10 mM NaOH for 0.5 min compared to 10 mM H3PO4 as applied in the ProteOn XPR36™.
Overall, the assay time, including transferring and mixing of the ERα and the standards/samples and
applying a 3 min injection at 30 µL/min and 1 min regeneration, was 11 min. These easy, fast and
stable conditions made the test more suitable for routine testing. An example of an unreferenced
(without the subtraction of the reference channel response) sensorgram is shown in Figure S6 and
referenced sensorgrams and the calibration curve are shown in Figure 3 and the LoD was determined
as 0.6 ng/mL.
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Figure 3. Referenced SPR sensorgrams obtained in the Biacore 3000 with E2 concentrations ranging
from 0 to 20 ng/mL. The standard solutions in 20% methanol and the wt-ERαLBD in HBS-EP (10 mM
Hepes, 150 mM NaCl, 3 mM EDTA, 0.005% Tween-20) buffer were transferred and mixed in the Biacore
(1:1; v/v). Of this ixture, 90 µL was i jected over the peptide-coated sensor surface at a flow rate
of 30 µL/min using HBS-EP as running bu fer. After the inject ons, the respo ses w re measured
(dotted line) n used for the construction of the calibration curve (insert). T e binding of the ER was
regenerated by the injection of 10 mM NaOH for 0.5 min. The total time of each cycle was 11 min of
which 5 min were used for the transfer and mixing.
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The optimized set-up was then used to test water samples with an expected level of EDCs in the
order of low ppt (pg/mL). Since our assay works at the low ppb level (range of the calibration curve
was from 0.5–10 ng/mL (Figure 3)), the water samples were concentrated up to 200 by SPE. In order to
prove the robustness of the bioassay, several water samples (millipore water (MQ), drinking water,
process water, water from a fish farm and river water samples) were tested with and without E2
spiking. MQ water sample was spiked with 0, 10, 20 and 50 ppt of E2, pre-concentrated by SPE from
50 to 0.25 mL (200 times), and the obtained responses (and recoveries) were 10, 80 (60%), 230 (64%)
and 370 RU (37%), respectively. Although the recoveries varied between 37 and 64%, the 10 ppt E2
addition was clearly detectable and the limit of detection was estimated at <5 ppt.
The tap water samples (n = 2) and the fish farm water samples (Figure S2 were also analysed
in the same way without and with the addition of 20 ppt of E2 and all spiked samples were clearly
detected with responses from 120 to 270 RUs (compared with responses of 5 to 18 RUs for the blanks)
and with recoveries varying from 38 to 75%.
Real water samples (n = 8) from fish farms in the UK (n = 3), Slovenia (n = 2 (Bay of Piran)) and
river water samples from Slovenia (n = 3), with and without the addition of 50 ppt of E2, were tested
after SPE with a 200 times concentration. Prior to their analysis, these real samples were hydrolysed
with Helix Pomatia overnight at 37 ◦C to convert possible conjugated estrogens (glucuronides and
sulphates) into the free compounds.
Sensorgrams of one of the water samples from the UK (SP3), with and without the addition of E2,
are shown in Figure S7 together with the responses (insert) obtained with all 8 samples and 2 standard
(10 ng/mL) responses for comparison (10 ng/mL = 100% recovery). The non-spiked real water samples
showed responses varying from 12 to 15 RU with an average of 14 ± 2 RU (corresponding with E2
concentrations in the samples of <5 ppt) and the spiked samples from 294 to 416 RU with an average
of 374 ± 39 RU (corresponding with an average recovery of 74 ± 7%). As controls, Millipore Q (MiliQ)
samples (n = 2) with and without the addition of 50 ppt of E2 were tested which resulted in comparable
average responses (12 ± 0 and 386 ± 54 RU) and a comparable recovery (81%).
Additional water samples (n = 4) taken from a Slovenian fish farm, Slovenian rivers (n = 2) and
the Gulf of Trieste were tested after a 500 times concentration by SPE and these resulted in an average
response of 10± 6 RU which corresponds with a concentration of E2 of <1 ppt. The MQ controls (blank
and spike at 10 ppt) gave responses of 15 and 469 RU with a recovery of 66%.
No positive water samples were found with the biosensor receptor test except for E2 spiked
samples. In order to confirm the results, the same samples were tested by GCMS and no E2 and EE2
and other steroids were detected (<5 ppt) and the average recovery of the 50 ppt spiked samples (n = 8)
was 76 ± 7%. The comparison of the data proves that wt-ERαLBD bioassay is reliable and it can be
successfully used to determine the amount of E2 in real water samples at low ppt levels.
3.4. Array of ERα Receptors Mutants
In this work, the SPR experiments have been performed to test the peptide-specific recognition
of the conformation of complexes formed by wt-ERαLBD and the mutants M421F-ERαLBD and
M421I-ERαLBD with agonist and antagonist compounds [28]. The mutant Y537S-ERαLBD has been
used as positive control because of its permanent ligand-bound mode or active conformation, even in
the absence of ligand. The permanent active conformation is due to the substitution of the Tyrosine
into Serine amino-acids [44].
Ligand-free receptor was used as a control resulting in a limited amount of interactions with
αβ/I peptides (Figure S8A–C, black line and Figure 4E). This unexpected binding is probably due
to the flexible structure of ERαLBD, which may lead to partially active conformation [45]. Besides,
the results also show that in the absence of ligand, αβ/I peptide is able to recognize the permanent
active conformation of Y537S-ERαLBD mutant (Figure 3D, black line).
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After incubation of ERαLBD receptors with 1.5 µM of E2, EE2, 4-NP or TAM, respectively,
different ERαLBD–ligands complexes were flowed over the peptides coated chip and the sensogram is
plotted in Figure S8.
In order to determine and compare the increase/decrease of SPR signal for the different ERαLBD
receptors and ligands, we define the parameter R as a ratio:
R =
IntensityERαLBD−ligand − Intensityfree−ERαLBD
Intensityfree−ERαLBD
This parameter indicates the increasing (or decreasing) amount of ERαLBD in the active
conformation normalized to free ERαLBD. In Figure 4, the parameter R (Active ERαLBD/ligand)
is plotted for each ERαLBD mutant (wt-ERαLBD, M421F-ERαLBD, M421I-ERαLBD, Y537S-ERαLBD) and
for the ligands E2, EE2, 4-NP and TAM.
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E2 and EE2, incubated with ERαLBD mutants provoke a clear positive ratio R with a modulated
response in the following order: Y537S-ERαLBD < wt-ERαLBD < M421I-ERαLBD < M421F-ERαLBD
(Figure 4, Panels A and B). This trend is probably due to the higher affinity of M421F-ERαLBD for E2
and EE2 [28] as compared to other receptor which results in a higher percentage of M421F-ERαLBD
in the active conformation, that is, higher recognition by αβ/I peptides. As expected, the ratio R
resulting from the binding of Y537S-ERαLBD complex formed with strong agonists to αβ/I peptide is
only marginally increased because of its natural, active conformation even in the absence of agonist
ligands as mentioned above [44].
The evidence of the Y537S-ERαLBD mutant being in a high percentage in the active conformation
is much clearer observing Figure 4E where it is possible to observe the different amount of the
ligand-free mutants being in active conformation (Y537S-ERαLBD > wt-ERαLBD > M421I-ERαLBD
> M421F-ERαLBD).
The SPR responses are noticeably different for TAM (Figure 4, Panel C) where the normalized
ratio (R) for all ERαLBD mutants is found negative since the SPR signal for ERαLBD -TAM complexes is
lower than the reference (ligand free ERαLBD). This result confirms the interaction between TAM and
the mutants binding pocket inducing a conformational change in an antagonist bound conformation,
which is not recognized by αβ/I peptide.
The weak agonist ligand 4-NP, generates a positive R for M421F-ERαLBD mutant (Figure 4D, cyan)
and negative R for the other mutants (Figure 4D). The lower affinity of 4-NP for ERαLBD does not allow
to establish a clear SPR response trend; however, the statistical relevance of the data is demonstrated
by t-test. In details, the comparison of the SPR response for ligand free and 4-NP bound wt-ERαLBD,
M421F-ERαLBD and M421I-ERαLBD are significantly different (p values calculated by t-test are 0.0002,
0.0002 and 0.0004, respectively) whereas for Y537S-ERαLBD the t-test is not significantly different
(p value 0.4154). From these analyses, it is tempting to say that the ‘positive /negative’ R pattern might
indicate the presence of weak agonists in an unknown sample.
These results suggest that the array of mutants can be used advantageously for a fast screening
of the presence of agonist/antagonist compounds in an unknown sample. In specific, clear positive
and negative R (R > 1 or R < 1) for the four receptors suggest the presence of an agonist or antagonist
compounds, respectively. The combination of positive and negative R might indicate the presence
of weak agonists. These different ratio pattern can thus give important information on the presence
or not of potential estrogenic compounds in unknown samples that have to be nevertheless further
identified in cellular environment.
To improve the identification capability of the compound by the present assay, more studies
need to be carried out focusing on the determination of the relative ratio R of the studied mutants
for more compounds at different concentrations. The large number of variable (concentration, EDCs
compounds with associated affinity towards ERαLBD) need to be integrated by an algorithm analysis
for further pattern recognition analysis.
The present assay is complementary to conventional methods of determination of (anti)estrogenic
activity traditionally performed by ER-CALUX, MELN, T47D-KBLuc and the Yeast Estrogen Screen
(YES) assays. These tests are all cells-based bioassays requiring stably transfected transcriptional
activation of responsive elements (luciferase for the three former assays and galactosidase for
the last) [7].
Indeed, the SPR assay developed in this study allows discriminating the presence of an antagonist
ligand from a situation where no ligand is present in a sample (see Figure 3). These two events are not
distinguishable on cell-based assays, unless a co-injection of an agonist is carried out. Furthermore,
the cell-based assay can be affected by different mechanisms, such as cytotoxicity and bioavailability of
the compounds, while the SPR response is a direct measurement of binding of a compound. In addition,
ERαLBD assay is performed in 1 h rather than 24 h as required for a cell-based assay. Moreover, being a
cell free assay, it does not need specific laboratory equipment and qualified personnel. Finally ERαLBD
assay can detect different compounds at the same time by using different ERαLBD mutants and
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multiple channels (Figure S1). The advantage of using a cell-based bioassays is the higher sensitivity
(20–40 pg/L for E2) [7] in comparison to ERαLBD assay (~20 ng/L for E2); however, the sensitivity
issue can be overcome by pre-concentrating the sample [43].
4. Conclusions
In conclusion, a SPR-based assay was designed for measuring the binding of agonist and
antagonist compounds to ERαLBD. This assay is based on the immobilization of αβ/I biotinylated
peptide, which specifically recognizes the conformational change of ERαLBD upon binding to E2.
This assay system allows easier detection of small molecules by SPR, since it is based on the ability
of the αβ/I peptide to specifically recognize the ERαLBD-E2 complex, thus leading to a great change
in SPR response. The limit of detection of the SPR assay is 0.60 ng/mL for wt-ERαLBD-E2 complex,
which can be improved by pre-concentrating the sample. E2 spiked real water sample were successfully
tested by wt-ERαLBD-E2 bioassay after SPE concentration and the results are in agreement with the
GC MS data. Moreover, an array of engineered estrogen receptors (wt-ERαLBD, M421F-ERαLBD,
M421I-ERαLBD and Y537S-ERαLBD) is screened with E2, EE2, 4-NP and TAM ligands.
The results show that the αβ/I peptide is able to distinguish between the ERαLBDs bound to
strong agonists, (E2, EE2), weak agonist (4-NP) and antagonist (TAM) molecules.
The assay which combines of the use of conformation-sensitive peptide and an array of ERα
mutants with different affinities toward EDC compounds is a very promising tool for detecting
the presence of/and potential estrogenic activity of chemicals through their binding to the ERαLBD.
In addition, the regeneration capability of the platform and its adaptability to a portable SPR device
make this assay promising for screening of EDCs in field.
Supplementary Materials: The following are available online at www.mdpi.com/2079-6374/8/1/1/s1.
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